Company intelligence / Profile preview

PharmaDrug Inc.

Ownership: Private
Development stage: Phase 1

Overview

PharmaDrug’s lead asset PD‑001 has completed stability studies supporting manufacturing for clinical trials. The company has initiated start-up activities for its first human clinical study targeting viral infectious diseases. Sairiyo Therapeutics received FDA orphan drug designation for cepharanthine in esophageal cancer.

Therapeutic areas: OtherOncologyNeurologyInfectious Diseases
Modalities: Reformulated natural products (e.g., cepharanthine)Synthetic formulations of existing drugsPsychedelics and controlled substancesCannabis-derived medicinesFunctional mushrooms/natural-based medicines
Industry: Biotech

Drug pipeline

1 asset

cepharanthine

Beyond the preview

Go deeper on PharmaDrug Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaDrug Inc..

Explore the full profile